Journal of Leukocyte Biology BioLegend: Treg, Th17, Stem Cell
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

A more recent version of this article appeared on March 1, 2007

Published online before print December 8, 2006
This Article
Right arrow Full Text (Reprint (PDF))
Right arrow All Versions of this Article:
jlb.0906549v1
81/3/632    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spellberg, B. J.
Right arrow Articles by Ibrahim, A. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spellberg, B. J.
Right arrow Articles by Ibrahim, A. S.
© by The Society for Leukocyte Biology
Journal of Leukocyte Biology, doi:10.1189/jlb.0906549

Received for publication September 5, 2006.
Revised October 27, 2006.
Accepted for publication November 10, 2006.

Article

Optimization of a myeloid cell transfusion strategy for infected neutropenic hosts

Brad J. Spellberg *{dagger}@, Mary Collins *, Valentina Avanesian *, Mayela Gomez *{ddagger}, John E. Edwards Jr.*{dagger}, Christopher Cogle {sect}, David Applebaum ||, Yue Fu *{dagger}, and Ashraf S. Ibrahim *{dagger}

*Division of Infectious Diseases and ||Department of Radiation Safety, Los Angeles Biomedical Research Institute, Harbor-University of California at Los Angeles (UCLA) Medical Center, and {dagger}The David Geffen School of Medicine at UCLA, Torrance, California, USA; {ddagger}California State University at Dominguez Hills, Carson, California, USA; and {sect}University of Florida Shands Cancer Center, Gainesville, Florida, USA

@ To whom correspondence should be addressed. E-mail: bspellberg{at}labiomed.org.


  Abstract

Although granulocyte transfusion is a logical, therapeutic option for neutropenic patients with refractory infections, significant technical barriers have prevented its widespread use. A novel phagocyte transfusion strategy has been developed based on activation of a human myeloid cell line HL-60. To further define the potential for HL-60 cells to recapitulate white cell transfusions, a shortened duration of activation was evaluated, facile quality control markers were defined, and the impact of low-dose irradiation on cell function was determined. Three days of activation resulted in increased cell viability and in vitro candidacidal capacity but with slightly higher cell replication compared with 7 days of activation. Cell viability and several flow cytometric measurements were accurate, quality control markers for HL-60 activation. In combination with activation, low-dose irradiation abrogated replication while sparing the candidacidal effects of the HL-60 cells. Infusion of irradiated, activated HL-60 cells improved survival of neutropenic, candidemic mice significantly. In summary, activated, irradiated HL-60 cells are microbicidal, have virtually no replicative capacity, and are safe and effective at protecting neutropenic mice against an otherwise 100% fatal candidal infection. With continued development, this strategy to recapitulate neutrophil functions has the potential to serve as an effective alternative to granulocyte transfusions.

Key Words: phagocyte • neutrophil • Candida




This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
A. S. Ibrahim, T. Gebremariam, Y. Fu, J. E. Edwards Jr., and B. Spellberg
Combination Echinocandin-Polyene Treatment of Murine Mucormycosis
Antimicrob. Agents Chemother., April 1, 2008; 52(4): 1556 - 1558.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2006 by the Society for Leukocyte Biology.